Daiichi Sankyo is expanding its research sites into the US and Europe, with one in Massachusetts and another in Germany, the Tokyo-based company announced Wednesday.
Operations will fire up at both sites by September this year in order to “build new, and deepen existing, partnerships in these world-renowned innovation hotspots,” according to Daiichi.
Ken TakeshitaDS Research Institute Boston will open in Cambridge, MA, with the new European site, DS Research Institute Munich, to operate in Munich, Germany. According to Daiichi’s website, it has 20 R&D sites in 12 different countries and regions, including New Jersey, Shanghai and Tokyo.
“By enhancing our presence in these regions and utilizing our strengths in science and technology, Daiichi Sankyo will continuously generate innovation through further collaborations with business partners and academia, contributing to the enrichment of quality of life around the world,” Daiichi global head of R&D Ken Takeshita wrote in a statement.
Daiichi has also been working on expanding its manufacturing this year, including a €1 billion ($1.07 billion) investment into a German facility to increase its capacity for antibody-drug conjugates manufacturing as well as other therapies for breast, lung and stomach cancers.